We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene Showcases Latest Molecular Testing Solutions at AACC 2022

By LabMedica International staff writers
Posted on 27 Jul 2022
Print article
Image: STARlet-AIOS provides an ultimate solution that can detect and diagnose the exact cause of symptoms (Photo courtesy of Seegene)
Image: STARlet-AIOS provides an ultimate solution that can detect and diagnose the exact cause of symptoms (Photo courtesy of Seegene)

Seegene, Inc. (Seoul, Korea) is showcasing its molecular testing solutions at the 2022 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo, July 24-28 in Chicago.

Seegene’s COVID-19 EUA and various Research Use molecular assays are designed to simultaneously detect multiple targets with high accuracy for infectious diseases such as Monkeypox, tick-borne, drug resistance, respiratory infections, STI, UTI, and more. Visitors to the company’s AACC 2022 booth can explore the Seegene In-Life PCR campaign, a global initiative that seeks to encourage regular testing of respiratory viruses, including COVID-19, flu, and colds, to stay protected from infectious diseases. It aims to curb widespread transmission and ensure a smooth return to normalcy by targeting those at community-based facilities like schools and nursing homes, as well as individuals that are asymptomatic.

Seegene’s EU-Approved Allplex SARS-CoV-2/FluA/FluB/RSV Assay is expected to help small hospitals, local clinics, and public health centers effectively identify COVID-19, influenza A and B and respiratory syncytial virus (RSV). The Allplex SARS-CoV-2/FluA/FluB/RSV Assay can detect six targets associated with the four respiratory viruses. The targets include three distinct COVID-19 genes (S, RdRp, N) to reliably identify positive cases even as new variants emerge. The test also includes two internal controls for proper sampling and testing validation. The product can deliver results within two hours when extraction-free, making it both time and cost-efficient.

Seegene’s Allplex SARS-CoV-2/FluA/FluB/RSV Assay is compatible with the company's fully automated 'AIOS' (All-in-One System). AIOS, the first fully automated high throughput MDx system for syndromic testing, supports "hands-free" PCR workflows – from nucleic acid extraction to PCR setup, gene amplification and results analysis. As AIOS is a fully automated (sample in – result out) system, it can be operated by those without PCR experience. AIOS is also compact in size and has over 30 compatible assays for syndromic testing to boost efficiency and utility, in contrast to conventional automated PCR solutions in the market that are bigger and have fewer applicable assays that detect only one to three specific targets.

AIOS is the world's first fully automated and "assembled" solution that composes independent and detachable instruments required for PCR, unlike other solutions that operate as a single unit. This makes AIOS convenient to use and maintain, while authorization procedures will be easier as existing instruments and assays can be applied. Such features are expected to allow small hospitals, local clinics, and public health centers to integrate AIOS into their workflows for PCR tests, which had been limited before due to lack of instruments or specialists to operate PCR solutions.

Seegene has also received CE-IVD marking for the saliva-based testing application for Allplex SARS-CoV-2 Assay and Allplex SARS-CoV-2/FluA/FluB/RSV Assay, and both the products with the feature are now available in Europe. The new addition of saliva sample collection feature is set to offload burden of collecting large volume of specimen samples for healthcare professionals on the frontlines of the COVID-19 pandemic. With the newly added feature, the saliva sample collection test can be used interchangeably with nasopharyngeal specimen collection test, normally used for multiplex real-time PCR tests for screening the novel coronavirus.

Seegene has also developed a PCR test to detect the monkeypox virus. The Novaplex MPXV Assay, which specifically targets the monkeypox virus, was developed using the company's AI-based automated test development system, known as SGDDS (Seegene Digitalized Development System), and technologies refined over 20 years of MDx expertise. The Novaplex MPXV Assay can identify positive cases of the monkeypox virus in 90 minutes.
 

Related Links:
Seegene, Inc.

Gold Member
Hematology Analyzer
Swelab Lumi
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Urine Drug Test
Instant-view Buprenorphine Urine Drug Test
New
H. pylori Test
STANDARD Q H. pylori Ab Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The kit includes a container with a film, a compact optical device for attaching a smartphone, and a diagnostic app (Photo courtesy of KIST)

Urine-Based Bladder Cancer Diagnostic Kit to Reduce Need for Unnecessary Cystoscopies

Bladder cancer has a high cure rate of over 90% when detected early, but it is characterized by a recurrence rate of 70%, which requires continuous monitoring. Late-stage detection often results in major... Read more

Microbiology

view channel
Image: The QIAstat-Dx mini gastrointestinal panel has secured U.S. clearance to support year-round outpatient care (Photo courtesy of QIAGEN)

Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions

Acute infectious gastroenteritis is a major cause of outpatient visits and hospitalizations in the U.S., with over 179 million cases estimated annually. Now, a new gastrointestinal panel designed to provide... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.